top of page

Proteasome inhibitors
(e.g., bortezomib, carfilzomib, ixazomib)

Cardio-oncological evaluation* AND BNP or NT-proBNP**

before cancer treatment begins

Cardio-oncological evaluation* AND home blood pressure monitoring, BNP or NT-proBNP**

every 3 months for 1 year, then every 6 months during all proteasome inhibitors therapy

* A cardio-oncological evaluation will systematically include at least one visit with blood pressure, blood glucose, lipid profile, GFR calculation, ECG and trans-thoracic echocardiography (TTE). Measurements of global longitudinal strain and 3D LVEF (if feasible) are recommended with the same machine.

** TTE and BNP/NT-proBNP must not be performed the day of proteasome inhibitor infusion

bottom of page